How A Therapeutic Use Exemption Is Reviewed

Some athletes have conditions treated with substances that appear on a prohibited list. An exemption process exists to allow that treatment, and it is a documented clinical review rather than a formality.

The criteria are cumulative and specific

An application must show a diagnosed condition requiring the substance, that no reasonable permitted alternative exists, and that the treatment would not enhance performance beyond a return to normal health.

All of the criteria must be met. A genuine diagnosis alone does not qualify if a permitted medication would treat the condition adequately.

A further criterion addresses causation: the need must not arise from prior use of a prohibited substance. This closes an obvious route to retrospective justification.

Documentation carries the application

Panels work from the medical file rather than from a narrative. Diagnostic test results, treatment history and the prescribing clinician's reasoning are the substance of the submission.

For conditions where diagnosis is contested, such as certain respiratory presentations, panels typically expect objective testing rather than symptom reports alone.

Incomplete files are the most common reason for rejection. The panel cannot assume facts, and a missing test result is treated as an absent criterion.

Panels are independent of the athlete's team

Applications are reviewed by physicians who are not part of the athlete's medical or coaching structure, and who have no stake in availability for competition.

That independence is the point. A treating doctor and a review panel weigh the same file with different obligations, and the process needs both perspectives recorded.

Reviewers may seek an additional expert opinion in a specialty, and applications are handled confidentially within the anti-doping organisation.

Timing depends on level and urgency

International-level athletes generally need approval in advance, while lower-level athletes may in some systems apply retroactively if tested.

Emergency treatment is handled retroactively by design, since a clinician managing an acute event cannot pause for administrative approval.

Approvals are time-limited and specific to substance, dose and route. Continuing treatment requires renewal, and a change of dose can require a fresh application.

Recognition and review across organisations

An exemption granted by one body is not automatically valid everywhere. Athletes moving between national and international testing pools may need recognition of an existing approval.

Higher authorities can review and reverse a grant, which acts as a check on inconsistent decisions between national organisations.

Aggregate data on exemptions is monitored for patterns, since an unusual concentration in a sport or a nation is a signal worth examining even when each individual file is sound.